This post was authored by Susan Scott, Octopus PPI (Patient and Public Involvement) Representative, member of the Trial Management Group, and Co-Applicant on the grant that funded the trial. It was originally published in the MS Society's North Herts newsletter. Two of us patient representatives on the Octopus trial were very honoured to fly to Toronto in December to an Intern ...
News
Next step for Octopus!
Octopus has now received the approvals needed for the trial to proceed. These are from the Health Research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and the Research Ethics Committee (REC). The chosen treatments are Metformin and R/S Alpha Lipoic Acid. Further details are available via the MS Society. The next steps are now to work with ...
Octopus trial up for approval by MHRA and Research Ethics Committee
The trial team at UCL has recently submitted their application to the Medicines and Healthcare products Regulatory Agency (MHRA) and to a Research Ethics Committee. Gaining approval from both these bodies is mandatory for the trial to open to recruitment. These organisations will review the application, raise any questions or request changes that they think are needed, and in ...
Octopus team publishes article on the trial's design
Clinicians and researchers involved in Octopus have published an article in the journal Neurology. This is one of the first scientific outputs from the trial. Octopus is the first trial in MS making use of the multi-arm multistage (MAMS) platform design. The goal is to speed up the evaluation of promising drugs against progressive MS by making the trial more efficient. The a ...
